Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizotinib Continuation Clinical Study
jRCT2041210125Active, not recruiting
- Sponsor
- Pfizer
- Start
- Dec 2021
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of crizotinib in non-small cell lung cancer (NSCLC), anaplastic large cell lymphoma (ALCL) and inflammatory pseudotumor (IPT), sponsored by Pfizer. Primary endpoints: Number of participants with adverse events leading to permanent discontinuation of study intervention and Number of serious adverse events reported for all participants. Started Dec 2021; status: active, not recruiting.
02
Drugs
crizotinib
03
Conditions
non-small cell lung cancer (NSCLC)anaplastic large cell lymphoma (ALCL)inflammatory pseudotumor (IPT)
Beyond the preview
Go deeper on jRCT2041210125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041210125.